<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
/ X / Quarterly Report pursuant to Section 13 or 15(d)
---- of the Securities and Exchange Act of 1934
For the quarterly period ended January 31, 1998.
or
/ / Transition Report pursuant to Section 13 or 15(d)
---- of the Securities and Exchange Act of 1934
For the transition period from _____ to _____.
Commission file number: 0-6132
CANTEL INDUSTRIES, INC.
-----------------------
(Exact name of registrant as specified in its charter)
Delaware 22-1760285
- ------------------------------- ----------------------------
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification no.)
1135 Broad Street, Clifton, New Jersey 07013-3346
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code
(973) 470-8700
--------------
Indicate by check mark whether registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to the filing
requirements for the past 90 days. Yes X No
----- -----
Number of shares of Common Stock outstanding as of March 6, 1998: 4,166,322.
<PAGE>
PART I - FINANCIAL INFORMATION
CANTEL INDUSTRIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollar Amounts in Thousands, Except Share Data)
(Unaudited)
January 31, July 31,
1998 1997
---------- ----------
ASSETS
Current assets:
Cash $ 570 $ 656
Accounts receivable 5,826 6,984
Inventories 9,120 8,974
Prepaid expenses and other current assets 483 395
------- -------
Total current assets 15,999 17,009
Property and equipment, at cost:
Furniture and equipment 2,047 2,009
Leasehold improvements 623 559
------- -------
2,670 2,568
Less accumulated depreciation and amortization (1,816) (1,801)
------- --------
854 767
Other assets 794 826
------- -------
$17,647 $18,602
------- -------
------- -------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 2,424 $ 3,732
Compensation payable 813 909
Other accrued expenses 663 706
Income taxes payable 88 556
------- -------
Total current liabilities 3,988 5,903
Long-term debt 2,300 1,594
Deferred income taxes 71 88
Stockholders' equity:
Preferred Stock, par value $1.00 per share;
authorized 1,000,000 shares; none issued -
Common Stock, $.10 par value; authorized 7,500,000
shares; issued and outstanding January 31
and July 31 - 4,166,322 shares 417 417
Additional capital 17,609 17,609
Accumulated deficit (4,871) (5,652)
Cumulative foreign currency translation adjustment (1,867) (1,357)
-------- -------
Total stockholders' equity 11,288 11,017
-------- -------
$17,647 $18,602
-------- -------
-------- -------
See accompanying notes.
1
<PAGE>
CANTEL INDUSTRIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Dollar Amounts in Thousands, Except Per Share Data)
(Unaudited)
Three Months Ended Six Months Ended
January 31, January 31,
1998 1997 1998 1997
------- ------- ------- -------
Net sales:
Product sales $ 9,384 $ 8,618 $16,614 $15,051
Product service 830 993 1,792 1,975
------- ------- ------- -------
Total net sales 10,214 9,611 18,406 17,026
------- ------- ------- -------
Cost of sales:
Product sales 6,343 5,693 11,308 9,937
Product service 444 600 981 1,229
------- ------- ------- -------
Total cost of sales 6,787 6,293 12,289 11,166
------- ------- ------- -------
Gross profit 3,427 3,318 6,117 5,860
Operating expenses:
Shipping and warehouse 168 162 311 303
Selling 1,156 1,136 2,107 2,030
General and administrative 1,006 936 1,838 1,773
Research and development 187 171 377 282
------- ------- ------- -------
Total operating expenses 2,517 2,405 4,633 4,388
------- ------- ------- -------
Income from operations before
interest expense and income
taxes 910 913 1,484 1,472
Interest expense 49 45 82 92
------- ------- ------- -------
Income before income taxes 861 868 1,402 1,380
Income taxes 373 426 621 716
------- ------- ------- -------
Net income $ 488 $ 442 $ 781 $ 664
------- ------- ------- -------
------- ------- ------- -------
Earnings per common share:
Basic $ .12 $ .11 $ .19 $ .17
------- ------- ------- -------
------- ------- ------- -------
Diluted $ .11 $ .10 $ .18 $ .15
------- ------- ------- -------
------- ------- ------- -------
See accompanying notes.
2
<PAGE>
CANTEL INDUSTRIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollar Amounts in Thousands)
(Unaudited)
Six Months Ended
January 31,
1998 1997
-------- --------
CASH FLOWS FROM OPERATING ACTIVITIES
Net income $ 781 $ 664
Adjustments to reconcile net income
to net cash (used in) provided by operating
activities:
Depreciation and amortization 130 161
Deferred income taxes (17) 7
Changes in assets and liabilities:
Accounts receivable 872 (986)
Inventories (548) (661)
Prepaid expenses and other current assets (101) (178)
Accounts payable and accrued expenses (1,257) 1,558
Income taxes payable (456) 292
-------- --------
Net cash (used in) provided by operating activities (596) 857
-------- --------
CASH FLOWS FROM INVESTING ACTIVITIES
Net additions to property and equipment (243) (172)
Other, net 54 74
-------- --------
Net cash used in investing activities (189) (98)
-------- --------
CASH FLOWS FROM FINANCING ACTIVITIES
Net borrowings (repayments) under credit facilities 699 (1,148)
Proceeds from exercise of stock options and warrants - 549
-------- --------
Net cash provided by (used in) financing activities 699 (599)
-------- --------
(Decrease) increase in cash (86) 160
Cash at beginning of period 656 682
-------- --------
Cash at end of period $ 570 $ 842
-------- --------
-------- --------
See accompanying notes.
3
<PAGE>
CANTEL INDUSTRIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1. BASIS OF PRESENTATION
The unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial reporting and the requirements of Form 10-Q and Rule 10.01 of
Regulation S-X. Accordingly, they do not include certain information and note
disclosures required by generally accepted accounting principles for annual
financial reporting and should be read in conjunction with the consolidated
financial statements and notes thereto included in the Annual Report of Cantel
Industries, Inc. (the "Company" or "Cantel") on Form 10-K for the fiscal year
ended July 31, 1997, and Management's Discussion and Analysis of Financial
Condition and Results of Operations included elsewhere herein. Cantel has two
wholly-owned subsidiaries, Carsen Group Inc. ("Carsen"), its Canadian
subsidiary, and MediVators, Inc. ("MediVators"), its United States subsidiary.
The unaudited interim financial statements reflect all adjustments which
management considers necessary for a fair presentation of the results of
operations for these periods. The results of operations for the interim periods
are not necessarily indicative of the results for the full year.
The condensed consolidated balance sheet at July 31, 1997 was derived from
the audited consolidated balance sheet of the Company at that date.
Certain items in the January 31, 1997 financial statements have been
reclassified from statements previously presented to conform to the presentation
of the January 31, 1998 financial statements.
Note 2. EARNINGS PER COMMON SHARE
Basic earnings per common share are computed based upon the weighted
average number of common shares outstanding during the period.
Diluted earnings per common share are computed based upon the weighted
average number of common shares outstanding during the period plus the dilutive
effect of options and warrants using the treasury stock method and the average
market price for the period.
4
<PAGE>
The following weighted average shares were used for the computation of
basic and diluted earnings per common share:
For the For the
three months ended six months ended
January 31, January 31,
--------------------- ---------------------
1998 1997 1998 1997
--------- --------- --------- ---------
Basic 4,166,322 4,071,804 4,166,322 3,981,803
--------- --------- --------- ---------
--------- --------- --------- ---------
Diluted 4,395,689 4,358,846 4,388,970 4,339,811
--------- --------- --------- ---------
--------- --------- --------- ---------
Earnings per common share for the three and six month periods ended January
31, 1997 have been restated in accordance with Statement of Financial Accounting
Standards No. 128, "Earnings Per Share", which standard has been adopted by the
Company effective January 1, 1998 and requires the presentation of basic and
diluted earnings per common share.
Note 3. FINANCING ARRANGEMENTS
The Company has two credit facilities, a $5,000,000 revolving credit
facility for Carsen and a $1,500,000 revolving credit facility for MediVators.
Pursuant to the terms of the Carsen revolving credit facility, borrowings
under such facility must be paid in full no later than December 31, 1999.
Borrowings outstanding at January 31, 1998 and July 31, 1997 are in Canadian
dollars and bear interest at rates ranging from lender's Canadian prime rate to
.75% above the prime rate, depending upon Carsen's debt to equity ratio. At
January 31, 1998, the lender's Canadian prime rate was 6.0% and Carsen's
outstanding borrowings bear interest at such prime rate. Subsequent to January
31, 1998, the lender's prime rate increased to 6.5% and Carsen's borrowings will
continue to bear interest at such prime rate. A commitment fee on the unused
portion of this facility is payable in arrears at a rate of .25% per annum, with
interest on borrowings payable monthly. There were $1,720,000 (U.S. dollars) of
borrowings outstanding under this facility at January 31, 1998.
Pursuant to the terms of the MediVators revolving credit facility,
borrowings under such facility must be paid in full no later than February 1,
1999. Borrowings bear interest at 1.5% above the lender's United States prime
rate. The lender's prime rate was 8.5% at January 31, 1998. A commitment fee
on the unused portion of this facility is payable in arrears at a rate of .5%
per annum, with interest on borrowings payable monthly. There were
5
<PAGE>
$532,000 of borrowings outstanding under this facility at January 31, 1998.
Each of the credit facilities provides for restrictions on available
borrowings based primarily upon percentages of eligible accounts receivable and
inventories; requires the subsidiary to meet certain financial covenants; are
secured by substantially all assets of the subsidiary; and are guaranteed by
Cantel.
Note 4. INCOME TAXES
Income taxes primarily consist of income taxes imposed on the Company's
Canadian operations. The effective tax rate on Canadian operations was 44.9%
and 44.6% for the six months ended January 31, 1998 and 1997, respectively.
For the six months ended January 31, 1997, the consolidated effective tax
rate is higher than the Canadian effective tax rate due to the fact that
losses generated by the combined U.S. operations could not be used to offset
income generated by the Canadian operations.
6
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS.
RESULTS OF OPERATIONS
The results of operations reflect the results of the Company's wholly-owned
Canadian subsidiary, Carsen Group Inc. ("Carsen" or "Canadian subsidiary") and
its wholly-owned U.S. subsidiary, MediVators, Inc. ("MediVators" or "United
States subsidiary"). The ensuing discussion should also be read in conjunction
with the Company's Annual Report on Form 10-K for the fiscal year ended July 31,
1997.
The following table gives information as to the net sales and the
percentage to the total net sales accounted for by each operating segment of the
Company.
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
January 31, January 31,
-------------------------- ------------------------
1998 1997 1998 1997
-------------------------- ------------------------
(Dollar amounts in thousands)
$ % $ % $ % $ %
----- ----- ----- ----- ----- ----- ----- -----
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Medical, Infection
Control and Scientific
Products:
Medical and
Infection Control
Products $ 5,150 50.4 $5,665 58.9 $ 8,986 48.8 $ 9,284 54.5
Scientific
Products 1,489 14.6 1,583 16.5 2,960 16.1 3,029 17.8
Product Service 830 8.1 993 10.3 1,792 9.7 1,975 11.6
Consumer Products 2,745 26.9 1,370 14.3 4,668 25.4 2,738 16.1
------- ----- ------ ----- ------- ----- ------- -----
$10,214 100.0 $9,611 100.0 $18,406 100.0 $17,026 100.0
------- ----- ------ ----- ------- ----- ------- -----
------- ----- ------ ----- ------- ----- ------- -----
</TABLE>
Net sales increased by $603,000, or 6.3%, to $10,214,000 for the three
months ended January 31, 1998, from $9,611,000 for the three months ended
January 31, 1997. Net sales increased by $1,380,000, or 8.1%, to $18,406,000
for the six months ended January 31, 1998, from $17,026,000 for the six months
ended January 31, 1997. These increases were principally attributable to
increased sales of Consumer Products, partially offset by decreased sales of
Medical and Infection Control Products.
The increased sales of Consumer Products for the three and six months ended
January 31, 1998 were primarily attributable to stronger demand for certain 35
mm and digital camera models and related accessories, some of which were not
available during the comparable fiscal 1997 periods. The decreased sales of
Medical and Infection Control Products for the three and six months ended
January 31, 1998 were primarily attributable to a decrease in demand for medical
products, partially offset by an increase in demand for infection control
products.
7
<PAGE>
Gross profit increased by $109,000, or 3.3%, to $3,427,000 for the three
months ended January 31, 1998, from $3,318,000 for the three months ended
January 31, 1997. Gross profit increased by $257,000, or 4.4%, to $6,117,000
for the six months ended January 31, 1998, from $5,860,000 for the six months
end January 31, 1997. The gross profit margins for the three and six months
ended January 31, 1998 were 33.6% and 33.2%, respectively, compared with 34.5%
and 34.4% for the three and six months ended January 31, 1997. The lower gross
profit margins were primarily attributable to more competitive sales of medical
products and increased sales of consumer products, which generally have lower
profit margins. These margin decreases were partially offset by an increase in
certain types of endoscope repairs which generally produce higher margins.
Shipping and warehouse expenses increased by $6,000 to $168,000 for the
three months ended January 31, 1998, from $162,000 for the three months ended
January 31, 1997. For the six months ended January 31, 1998, shipping and
warehouse expenses increased by $8,000 to $311,000, from $303,000 for the six
months ended January 31, 1997.
Selling expenses as a percentage of net sales decreased to 11.3% and 11.4%
for the three and six months ended January 31, 1998, from 11.8% and 11.9% for
the three and six months ended January 31, 1997. These decreases were
principally attributable to the impact of the increased sales for the three and
six months ended January 31, 1998 against the fixed portion of these expenses,
partially offset by an increase in advertising costs.
General and administrative expenses increased by $70,000 to $1,006,000 for
the three months ended January 31, 1998, from $936,000 for the three months
ended January 31, 1997. For the six months ended January 31, 1998, general and
administrative expenses increased by $65,000 to $1,838,000, from $1,773,000 for
the six months ended January 31, 1997. These increases were primarily
attributable to increased personnel costs and regulatory compliance costs for
ISO 9000 certification.
Research and development expenses increased by $16,000 to $187,000 for the
three months ended January 31, 1998, from $171,000 for the three months ended
January 31, 1997. For the six months ended January 31, 1998, research and
development expenses increased by $95,000 to $377,000, from $282,000 for the six
months ended January 31, 1997. These increases were substantially due to the
ongoing development of infection control products at MediVators.
Interest expense increased to $49,000 for the three months ended January
31, 1998, from $45,000 for the three months ended January 31, 1997. For the six
months ended January 31, 1998, interest expense decreased to $82,000, from
$92,000 for the six months ended January 31, 1997.
8
<PAGE>
Income before income taxes increased by $22,000 to $1,402,000 for the six
months ended January 31, 1998, from $1,380,000 for the six months ended January
31, 1997.
Income taxes primarily consist of income taxes imposed on the Company's
Canadian operations. The effective tax rate on Canadian operations was 44.9%
and 44.6% for the six months ended January 31, 1998 and 1997, respectively.
For the six months ended January 31, 1997, the consolidated effective tax
rate is higher than the Canadian effective tax rate due to the fact that
losses generated by the combined U.S. operations could not be used to offset
income generated by the Canadian operations.
LIQUIDITY AND CAPITAL RESOURCES
At January 31, 1998, the Company's working capital was $12,011,000,
compared with $11,106,000 at July 31, 1997. This increase primarily reflects
decreases in accounts payable and income taxes payable, partially offset by a
decrease in accounts receivable.
Net cash used in operating activities was $596,000 for the six months ended
January 31, 1998, compared with net cash provided by operating activities of
$857,000 for the six months ended January 31, 1997. For the six months ended
January 31, 1998, the net cash used in operating activities was primarily due to
decreases in accounts payable and accrued expenses and income taxes payable, and
an increase in inventories, partially offset by income from operations after
adjusting for depreciation and amortization and a decrease in accounts
receivable. For the six months ended January 31, 1997, the net cash provided by
operating activities was primarily due to income from operations after adjusting
for depreciation and amortization and an increase in accounts payable and
accrued expenses, partially offset by increases in accounts receivable and
inventories.
Net cash used in investing activities was $189,000 for the six months ended
January 31, 1998 and $98,000 for the six months ended January 31, 1997 which was
principally due to additions to property and equipment.
Net cash provided by financing activities was $699,000 for the six months
ended January 31, 1998, compared with net cash used in financing activities of
$599,000 for the six months ended January 31, 1997. These changes were
principally due to the fluctuations in outstanding borrowings under the
Company's revolving credit facilities, partially offset during the six months
ended January 31, 1997 by proceeds from the exercise of stock options and
warrants.
The Company has two credit facilities, a $5,000,000 revolving credit
facility for Carsen and a $1,500,000 revolving credit
9
<PAGE>
facility for MediVators as described in Note 3 to the Condensed Consolidated
Financial Statements.
A decrease in the value of the Canadian dollar against the United States
dollar could adversely affect the Company because the Company's Canadian
subsidiary purchases substantially all of its products in United States dollars
and sells its products in Canadian dollars. Under the Canadian credit facility,
the Company's Canadian subsidiary has a foreign exchange hedging facility of up
to $15,000,000 (U.S. dollars) which could be used to minimize future adverse
currency fluctuations as they relate to purchases of inventories. The Canadian
subsidiary has foreign exchange forward contracts at March 6, 1998 aggregating
$6,000,000 (U.S. dollars) to hedge against the decline in the value of the
Canadian dollar which would otherwise result in higher inventory costs. Such
contracts represented the Canadian subsidiary's projected purchases of
inventories through May 1998. The average exchange rate of the contracts open
at March 6, 1998 was $1.3596 Canadian dollar per United States dollar, or $.7355
United States dollar per Canadian dollar. The exchange rate published by the
Wall Street Journal on March 6, 1998, was $1.4198 Canadian dollar per United
States dollar, or $.7043 United States dollar per Canadian dollar. Such adverse
currency fluctuations could also result in a corresponding adverse change in the
United States dollar value of the Company's assets that are denominated in
Canadian dollars. During the six months ended January 31, 1998, such adverse
currency fluctuations reduced stockholders' equity by $510,000.
The Company believes that its anticipated cash flow from operations and the
funds available under the credit facilities will
be sufficient to satisfy the Company's cash operating requirements for its
existing operations for the foreseeable future. At March 6, 1998, $3,911,000
was available under the credit facilities.
Inflation has not significantly impacted the Company's operations.
10
<PAGE>
PART II - OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
On January 22, 1998, the Company held its Annual Meeting of Stockholders.
At the meeting, Richard L. Bloch, Darwin C. Dornbush and Morris W. Offit were
re-elected directors of the Company, to hold office until the Annual Meeting of
Shareholders to be held after the fiscal year ending July 31, 2000, and James P.
Reilly and Robert L. Barbanell were re-elected directors of the Company, to hold
office until the Annual Meeting of Stockholders to be held after the fiscal year
ending July 31, 1999. 3,588,141 votes were cast for, 11,215 votes were
withheld, and 0 votes abstained in the election of each of these directors.
In addition, the stockholders approved the appointment of the firm Ernst &
Young LLP to audit the financial statements of the Company for the fiscal year
ending July 31, 1998. 3,584,429 votes were cast for, 7,889 votes were against,
and 7,038 votes abstained in the appointment of Ernst & Young LLP.
Stockholders also approved the 1997 Employee Stock Option Plan, under which
options may be granted to employees for an aggregate of 200,000 shares of the
Company's Common Stock. 3,559,569 votes were cast for, 35,755 votes were
against, and 4,032 votes abstained in the approval of the 1997 Employee Stock
Option Plan.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
Exhibit 11, Computation of Earnings Per Share
Exhibit 27, Financial Data Schedule
(b) Reports on Form 8-K
There were no reports on Form 8-K filed for the three months
ended January 31, 1998.
11
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
CANTEL INDUSTRIES, INC.
Date: March 12, 1998 By: /s/ James P. Reilly
--------------------------
James P. Reilly, President
and Chief Executive Officer
(Principal Executive Officer
and Principal Financial Officer)
By: /s/ Craig A. Sheldon
--------------------------
Craig A. Sheldon, Vice
President and Controller
(Chief Accounting Officer)
12
<PAGE>
EXHIBIT 11
CANTEL INDUSTRIES, INC.
COMPUTATION OF EARNINGS PER SHARE
Three Months Ended Six Months Ended
January 31, January 31,
1998 1997 1998 1997
--------- --------- --------- ---------
BASIC
Weighted average number of
shares outstanding 4,166,322 4,071,804 4,166,322 3,981,803
--------- --------- --------- ---------
--------- --------- --------- ---------
Net income $ 488,000 $ 442,000 $ 781,000 $ 664,000
--------- --------- --------- ---------
--------- --------- --------- ---------
Earnings per common share $ 0.12 $ 0.11 $ 0.19 $ 0.17
------ ------ ------ ------
------ ------ ------ ------
DILUTED
Weighted average number of
shares outstanding 4,166,322 4,071,804 4,166,322 3,981,803
Dilutive effect of options and
warrants using the treasury
stock method and the average
market price for the period 229,367 287,042 222,648 358,008
--------- --------- --------- ---------
Weighted average number of
shares and common stock
equivalents 4,395,689 4,358,846 4,388,970 4,339,811
--------- --------- --------- ---------
--------- --------- --------- ---------
Net income $ 488,000 $ 442,000 $ 781,000 $ 664,000
--------- --------- --------- ---------
--------- --------- --------- ---------
Earnings per common share $ 0.11 $ 0.10 $ 0.18 $ 0.15
------ ------ ------ ------
------ ------ ------ ------
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED BALANCE SHEET AT JANUARY 31, 1998 AND THE CONDENSED
CONSOLIDATED STATEMENT OF INCOME FOR THE SIX MONTHS ENDED JANUARY 31, 1998
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> JUL-31-1998
<PERIOD-END> JAN-31-1998
<CASH> 570,000
<SECURITIES> 0
<RECEIVABLES> 5,826,000
<ALLOWANCES> 0
<INVENTORY> 9,120,000
<CURRENT-ASSETS> 15,999,000
<PP&E> 2,670,000
<DEPRECIATION> 1,816,000
<TOTAL-ASSETS> 17,647,000
<CURRENT-LIABILITIES> 3,988,000
<BONDS> 2,300,000
0
0
<COMMON> 417,000
<OTHER-SE> 10,871,000
<TOTAL-LIABILITY-AND-EQUITY> 17,647,000
<SALES> 16,614,000
<TOTAL-REVENUES> 18,406,000
<CGS> 11,308,000
<TOTAL-COSTS> 12,289,000
<OTHER-EXPENSES> 4,633,000
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 82,000
<INCOME-PRETAX> 1,402,000
<INCOME-TAX> 621,000
<INCOME-CONTINUING> 781,000
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 781,000
<EPS-PRIMARY> 0.19
<EPS-DILUTED> 0.18
</TABLE>
